BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22277459)

  • 1. [Current status and future of anti-Xa inhibitors].
    Nagao T
    Rinsho Shinkeigaku; 2011 Nov; 51(11):1007-10. PubMed ID: 22277459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Piccini JP; Lopes RD; Mahaffey KW
    Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
    Mangiafico RA; Mangiafico M
    Curr Med Chem; 2012; 19(27):4688-98. PubMed ID: 22830344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anticoagulants for atrial fibrillation.
    Sobieraj-Teague M; O'Donnell M; Eikelboom J
    Semin Thromb Hemost; 2009 Jul; 35(5):515-24. PubMed ID: 19739042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thromboembolic prophylaxis 2011: is warfarin on the wane?].
    Di Pasquale G; Riva L
    G Ital Cardiol (Rome); 2011 Sep; 12(9):556-65. PubMed ID: 21892216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
    Bommer WJ
    Crit Pathw Cardiol; 2012 Jun; 11(2):45-54. PubMed ID: 22595814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New oral anticoagulants for atrial fibrillation: a review of clinical trials.
    O'Dell KM; Igawa D; Hsin J
    Clin Ther; 2012 Apr; 34(4):894-901. PubMed ID: 22417716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
    Yoon CH; Park YK; Kim SJ; Lee MJ; Ryoo S; Kim GM; Chung CS; Lee KH; Kim JS; Bang OY
    Stroke; 2014 Oct; 45(10):2983-8. PubMed ID: 25147329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.